Last reviewed · How we verify
contrast agent, Gadolinium
At a glance
| Generic name | contrast agent, Gadolinium |
|---|---|
| Sponsor | Hôpital Fribourgeois |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Evaluation of Gadolinium Based Contrast Agents for Portable MR Imaging Systems (NA)
- Reducing the Incidence of Symptomatic Brain Metastases With MRI Surveillance (PHASE2)
- Dotarem vs Gadobutrol Contrast for Breast MRI (PHASE4)
- Metabolic Characteristics of Brain Tumors Using Hyperpolarized Carbon-13 Magnetic Resonance Spectroscopic Imaging (MRSI)
- A Prospective Registry for Patients at High-Risk for Pancreatic Cancer
- Effects of Relugolix vs Leuprolide on Cardiac Function in Patients With Prostate Cancer (PHASE2)
- Using Advanced Imaging Studies to Develop a Profile of High-grade Serous Ovarian Cancer (NA)
- Spinal Cord Lesion Detection in Multiple Sclerosis Using Novel MRI Sequences (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- contrast agent, Gadolinium CI brief — competitive landscape report
- contrast agent, Gadolinium updates RSS · CI watch RSS
- Hôpital Fribourgeois portfolio CI